Posted On: 07/15/2014 7:30:53 AM
Post# of 63802
$EXEL breakout gap candle Pr. $4.09
Website
Exelixis Announces Positive Top-Line Results
for Phase 3 Pivotal Trial of Cobimetinib in Combination With
Vemurafenib in Patients With BRAF V600 Mutation-Positive
Advanced Melanoma
2014-07-14 01:00 ET - News Release
O/S shares 194,694,949
10-Q 5/1/14
Website
Exelixis Announces Positive Top-Line Results
for Phase 3 Pivotal Trial of Cobimetinib in Combination With
Vemurafenib in Patients With BRAF V600 Mutation-Positive
Advanced Melanoma
2014-07-14 01:00 ET - News Release
O/S shares 194,694,949
10-Q 5/1/14
(0)
(0)Scroll down for more posts ▼
